The isomorphic laboratories, the AI medication discovery platform which was removed from Deepmind de Google in 2021, raised external capital for the first time. The round of $ 600 million was led by Thrive Capital, with the participation of GV and the alphabet of the parents of the existing Google investor, He said.
Funding will accelerate the subsequent development of the IA medication design engine from the isomorph and support the company’s objective to bring its discovered drugs to clinical trials.
The isomorphic laboratories were founded by the co-founder Deepmind Demis Hassabis by taking advantage of Deepmind software for the discovery of AI drugs, including Alphafold, an AI model that predicts the three-dimensional protein structures.
Last year, isomorphic laboratories obtained strategic partnerships with Eli Lilly and Novartis, potentially generating up to $ 3 billion in significant payments for access to its AI model.
Hassabis said The New York Times That even if the isomorphic laboratories did not need the capital, additional funding will help the division to hire the best researchers.
For their work on Alphafold, Hassabis and researcher Deepmind, John Jumper, were among the three scientists who received a Nobel Prize in chemistry in 2024.
